Kaspofungin Rhei (Caspofungin)

Caspofungin blocks the enzyme β‑(1,3)‑D‑glucan synthase, preventing the synthesis of β‑(1,3)‑D‑glucan, an essential component of the fungal cell wall. The resulting weakness in the wall leads to osmotic instability and fungal cell death, while human cells are unaffected because they lack this pathway.

The dosing regimen for caspofungin is individualized by the prescribing clinician based on the infection type, severity, patient weight, and organ function. Healthcare professionals determine the appropriate loading and maintenance doses and adjust them according to clinical response and laboratory monitoring.

Safety data for caspofungin in pregnancy and lactation are limited. The drug should be used only if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and necessary import documentation.

Caspofungin belongs to the echinocandin class, which targets the fungal cell wall, whereas azoles (e.g., fluconazole) inhibit ergosterol synthesis in the cell membrane. Echinocandins are often preferred for resistant Candida species and for patients who cannot tolerate azoles, but they require intravenous administration, whereas many azoles are available orally.

The product must be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Before use, allow the solution to reach room temperature if required, and inspect for particulate matter or discoloration. Follow aseptic technique during preparation and administration.

Kaspofungin Rhei is administered as an intravenous infusion. A typical protocol involves an initial loading dose followed by daily maintenance infusions, each diluted in compatible IV fluid and infused over a specified period. Administration must be performed by qualified healthcare personnel in a clinical setting.

Serious adverse events include severe hypersensitivity reactions such as anaphylaxis, hepatic failure with marked enzyme elevation, acute renal injury, profound hypotension during infusion, and rare skin disorders like Stevens‑Johnson syndrome. Prompt recognition and discontinuation of the drug are essential if any of these occur.

Patients with known hypersensitivity to caspofungin or any component of the formulation should avoid the product. Caution is also advised for individuals with severe hepatic impairment, uncontrolled cardiac disease, or those receiving interacting medications that could significantly alter drug exposure. The prescriber should evaluate each case individually.